恒瑞医药：二十碳五烯酸乙酯软胶囊获批上市

Core Viewpoint - Heng Rui Medicine (600276) announced the approval of its subsidiary Chengdu Shengdi Pharmaceutical Co., Ltd. for the market launch of Eicosapentaenoic Acid Ethyl Ester Soft Capsules by the National Medical Products Administration [1] Group 1 - The approval signifies a regulatory milestone for the company, potentially enhancing its product portfolio [1] - Eicosapentaenoic Acid Ethyl Ester is known for its health benefits, which may attract consumer interest and drive sales [1] - The launch could strengthen the company's position in the pharmaceutical market, particularly in the area of dietary supplements [1]